Semper Paratus Acquisition Corp

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company. It develops off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company was founded on February 14, 2024 and is headquartered in Warren, NJ.

WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings ('Tevogen Bio') (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as Managing Director of Risk Advisory Services at Verita CSG, Inc., a provider of holistic insurance and risk management solutions for commercial line clients. Mr. Sordillo has been a vital part of Tevogen's Board of Directors, contributing to the diversity of thought leadership within the executive team by way of expertise in leadership, risk.

Tevogen Bio Holdings Congratulates its Board Member and Esteemed Global Safety Management Expert, Victor Sordillo, on His appointment as Managing Director of Risk Advisory Services at Verita

WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings – Tevogen (Nasdaq: TVGN) Chief Information Officer and Head of company's Artificial Intelligence Initiative, Tevogen.ai, Mittul Mehta, has taken strides to emphasize the importance of proactive talent development for biopharmaceutical sector to allow rapid adoption of artificial intelligence (AI). In his recent seminar at the Yale School of Public Health, “Artificial Intelligence Opportunities in Healthcare,” he underscored the potential of AI.

Mittul Mehta, Head of Tevogen's Artificial Intelligence Initiative Tevogen.ai, Emphasizes Importance of Proactive Talent Development for Biopharmaceutical Sector to Allow Rapid Adoption of AI

WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) Tevogen's ExacTcell platform was developed to harness the killing ability of naturally occurring cytotoxic T lymphocytes (CTLs), against viral and malignant targets. TVGN 489, a CTL therapy produced by the ExactTcell platform, contains CTLs recognizing multiple protein targets across the SARS-CoV-2 genome. These cells were well tolerated in a completed proof of concept clinical trial in high-risk patients wi.

Cell Therapy Company Tevogen Bio Holdings Inc. Prepares to Launch Crucial Genetic Predisposition Study in Preparation to Investigate the Potential of TVGN 489 to Address Critical Unmet Need for Long COVID Treatment

WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in Times Square, New York, on February 15th, 2024. This major milestone underscored the company's commitment to its valued shareholders and its mission to develop commercially attractive, affordable, genetically unmodified off-the-shelf T cell therapies for large patient populations in virology, oncology, a.

Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings Opening Bell at Nasdaq Exchange on February 15th, 2024, Begins Public Trading on the Open Market

WARREN, N.J.--(BUSINESS WIRE)--On February 14, 2024, Tevogen Bio Holdings Inc. (the “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, entered into a securities purchase agreement with an investor pursuant to which the investor agreed to purchase shares of Series A Preferred Stock of the Company for an aggregate purchase price of $8.0 million. “We are excit.

Tevogen Bio Announces $8 Million Equity Investment

WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen Bio”), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc's previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc. The combined company's common stock and warrants will begin trading on Nasdaq Global Market (“Nasdaq”) under the ticker symbols TVGN and TVGNW, respectively, beginning Thursday, February 15, 2024.

Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion of Business Combination and is to be Listed on Nasdaq Under Ticker TVGN

News for Semper Paratus Acquisition Corp Stock (TVGN)